Does Zetia Cause Abdominal Pain?
Yes, abdominal pain is a recognized adverse effect of Zetia (ezetimibe), though it occurs infrequently and is generally mild. According to FDA labeling, abdominal pain has been reported in post-marketing surveillance and in clinical trials when ezetimibe is combined with bempedoic acid 1.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for Zetia explicitly lists stomach pain among the adverse effects reported in general use 1. When ezetimibe is combined with bempedoic acid, abdominal pain or discomfort appears as a documented adverse effect 2.
In controlled clinical trials:
- Monotherapy studies (2,396 patients): Abdominal pain was not among the most common adverse reactions (≥2% incidence) 1
- The most frequent side effects with ezetimibe alone were upper respiratory tract infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), sinusitis (2.8%), and pain in extremity (2.7%) 1
- Combination therapy with statins (11,308 patients): Similarly, abdominal pain did not reach the ≥2% threshold for common adverse reactions 1
Clinical Context and Severity
The abdominal pain associated with ezetimibe is typically mild and does not require treatment discontinuation in most cases. The 2022 ACC Expert Consensus describes ezetimibe as "generally well tolerated" 2.
Important Caveats:
- Pancreatitis: While extremely rare, inflammation of the pancreas has been reported with ezetimibe use and would present as severe abdominal pain requiring immediate medical attention 1
- Gallbladder issues: Gallstones and inflammation of the gallbladder have been reported, which can manifest as abdominal pain 1
- Gastrointestinal events overall: A systematic review of 18 randomized trials (14,471 patients) found no significant increase in gastrointestinal adverse events when ezetimibe was added to statin therapy compared to statin alone 3
Clinical Recommendation
If a patient on Zetia develops abdominal pain, evaluate for:
- Severity and characteristics - Mild, transient discomfort versus severe, persistent pain
- Associated symptoms - Nausea, vomiting, fever (suggesting pancreatitis or cholecystitis)
- Timing - Relationship to medication initiation
- Other causes - Consider alternative etiologies unrelated to ezetimibe
For mild, isolated abdominal discomfort without concerning features, continuation of ezetimibe is reasonable with monitoring. For severe or persistent abdominal pain, particularly with elevated pancreatic enzymes or signs of gallbladder disease, discontinue ezetimibe and investigate further 1.
The overall safety profile supports that while abdominal pain can occur with Zetia, it is uncommon and rarely leads to treatment discontinuation (3.3% discontinued in monotherapy trials, similar to placebo at 2.9%) 1.